Item 1. Security and Issuer
This Schedule 13D (“Schedule 13D”) relates to shares of common stock, par value $0.00001 per share (“Common Stock”), of Cepton, Inc., a Delaware corporation, formerly known as Growth Capital Acquisition Corp. (the “Issuer”). The principal executive offices of the Issuer are located at 399 West Trimble Road, San Jose, CA 95131.
Item 2. Identity and Background
This Schedule 13D is being filed by Koito Manufacturing Co., Ltd., a corporation organized under the laws of Japan (the “Reporting Person”). The Reporting Person’s principal business is the manufacturing and marketing of automotive lighting equipment, aircraft parts, electrical equipment and other products. The business address for the Reporting Person is 4-8-3, Takanawa, Minato-ku, Tokyo 108-8711, Japan.
During the last five years, the Reporting Person was not (i) convicted in a criminal proceeding (excluding
traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
Initial Acquisition of Securities from Legacy Cepton:
The Reporting Person initially acquired shares of Series C Preferred Stock, par value $0.00001 per share (the “Series C Preferred Stock”), of Cepton Technologies, Inc., a Delaware corporation (“Legacy Cepton”), for aggregate consideration of approximately $50.0 million, in February 2020. These shares were purchased using available cash of the Reporting Person. In connection therewith, the Reporting Person entered into an agreement with Legacy Cepton, pursuant to which (among other things) Legacy Cepton granted to the Reporting Person certain first offer rights with respect to sourcing specified sensor components, and the agreement also provides for certain obligations of the Reporting Person and Legacy Cepton to negotiate and enter into a manufacturing and supply agreement upon specified conditions and for a specified customer, and provides for an obligation of the Reporting Person and Legacy Cepton to explore certain potential joint development projects. In addition, as the holder of a majority of the Series C Preferred Stock, pursuant to an investor rights agreement signed in connection with such Series C Preferred Stock purchase, the Reporting Person had the right to appoint one (1) director to the board of directors of Legacy Cepton, subject to specified conditions.
Acquisition of Securities in SPAC Transaction:
Growth Capital Acquisition Corp. (“GCAC”), Legacy Cepton, and GCAC Merger Sub, Inc. (“Merger Sub”) entered into that certain Business Combination Agreement dated August 4, 2021, as amended by the Amendment to the Business Combination Agreement, dated January 21, 2022 (the “BCA”), pursuant to which Merger Sub merged with and into Legacy Cepton effective February 10, 2022 (the “Merger”), with Legacy Cepton surviving the Merger as a wholly owned subsidiary of GCAC upon the closing of the transactions contemplated therein. In connection with the closing of the Merger on February 10, 2022, GCAC filed a Second Amended and Restated Certificate of Incorporation with the Delaware Secretary of State pursuant to which, among other things, the name of GCAC was changed to Cepton, Inc.
Immediately prior to the effective time of the Merger, each issued and outstanding share of Class F stock of Legacy Cepton and of each series of preferred stock of Legacy Cepton (including the Series C Preferred Stock) was automatically converted into shares of common stock of Legacy Cepton (“Legacy Cepton Common Stock”). At the effective time of the Merger, each issued and outstanding share of Legacy Cepton Common Stock was converted into the right to receive 2.449 shares of Common Stock. In addition, each issued and outstanding share of Legacy Cepton Common Stock received a contingent right to receive a pro rata portion of (i) 7,000,000 shares of Common Stock, issuable (a) if the closing share price of the Common Stock equals or exceeds $15.00 per share for any 20 trading days within any consecutive 30-trading day period that occurs after the closing date of the Merger and on or prior to the three-year anniversary of the closing date of the Merger (the “$15.00 Share Price Milestone”) or (b) upon a change in control of the Issuer, as provided in the BCA, and (ii) an additional 6,000,000 shares of Common Stock, issuable (a) if the closing share price of the Common Stock equals or exceeds $17.50 per share for any 20 trading days within any consecutive 30-trading day period that occurs after the closing date of the Merger and on or prior to the three-year anniversary of the closing date of the Merger (the “$17.50 Share Price Milestone”) or (b) upon a change in control of the Issuer, as provided in the BCA.